Loading...
XTSE
APLI
Market cap1mUSD
Jun 10, Last price  
0.02CAD
1D
0.00%
1Q
-57.14%
IPO
-98.00%
Name

Appili Therapeutics Inc

Chart & Performance

D1W1MN
XTSE:APLI chart
No data to show
P/E
P/S
2.20
EPS
Div Yield, %
Shrs. gr., 5y
31.98%
Rev. gr., 5y
%
Revenues
827k
+147.60%
000199,10601,390,684334,177827,407
Net income
-4m
L-59.09%
-1,754,275-3,976,115-4,330,984-5,416,496-14,325,112-25,118,299-9,243,014-3,780,910
CFO
-2m
L-75.59%
-2,137,311-3,304,178-3,457,082-4,260,309-11,450,650-19,081,182-10,097,836-2,464,425
Earnings
Jun 23, 2025

Profile

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
IPO date
Jun 25, 2019
Employees
8
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
827
147.60%
334
-75.97%
Cost of revenue
8,813
8,441
Unusual Expense (Income)
NOPBT
(7,986)
(8,106)
NOPBT Margin
Operating Taxes
70
36
Tax Rate
NOPAT
(8,055)
(8,143)
Net income
(3,781)
-59.09%
(9,243)
-63.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,214
BB yield
-70.65%
Debt
Debt current
7,310
113
Long-term debt
875
7,552
Deferred revenue
Other long-term liabilities
(7,552)
Net debt
8,090
5,199
Cash flow
Cash from operating activities
(2,464)
(10,098)
CAPEX
(30)
(3)
Cash from investing activities
(29)
(3)
Cash from financing activities
122
5,908
FCF
(5,348)
(8,115)
Balance
Cash
94
2,466
Long term investments
Excess cash
53
2,449
Stockholders' equity
(26,770)
(13,810)
Invested Capital
24,030
14,037
ROIC
ROCE
291.45%
EV
Common stock shares outstanding
121,266
113,732
Price
0.04
-12.50%
0.04
-66.67%
Market cap
4,244
-6.70%
4,549
-43.19%
EV
12,335
9,749
EBITDA
(7,972)
(8,100)
EV/EBITDA
Interest
1,631
1,096
Interest/NOPBT